Clinical Trials Logo

Filter by:
NCT ID: NCT03585179 Not yet recruiting - Melasma Clinical Trials

Oral and Topical Tranexamic Acid for the Treatment of Melasma

TRANEXAMICO
Start date: August 1, 2018
Phase: Phase 3
Study type: Interventional

Tranexamic acid has been used for treating melasma due to its effect on decreasing the activity of tyrosinase and melanogenesis. This 3-arm clinical trial will asess the efficacy and safety of oral and topical tranexamic acid as monotherapy compared with topical hydroquinone for 12 weeks in adults with melasma. The primary outcome will be the percentage of reduction at 12-week period of mMASI and melanin index. The incidence of adverse effects will be reported at weeks 4, 8 and 12.

NCT ID: NCT03588052 Not yet recruiting - Gingival Recession Clinical Trials

Evaluation of Esthetic Root Coverage Using Platelet-Rich Fibrin Versus Subepithelial Connective Tissue Graft With Vestibular Incision Subperiosteal Tunnel Access in Multiple Gingival Recessions

Start date: August 1, 2018
Phase: N/A
Study type: Interventional

Patients with gingival recession, complain of excessive tooth length that affects their appearance during smiling or functioning. The main goal of plastic periodontal surgeries is to restore patient's esthetic demands with the regeneration of gingival and periodontal tissues. Although SCTG is considered a gold standard, it has its own limitations like patient morbidity and graft availability. Consequently, PRF has been introduced in an attempt to overcome the drawbacks of SCTG and achieve optimum results in root coverage. The minimally invasive VISTA technique allows better access with coronal positioning and stabilization of gingival margin to achieve complete root coverage. In addition to platelets-rich fibrin that gives a predictable and reproducible result in restoring the amount of keratinized tissue, root coverage and better esthetic outcome. The use Vestibular incision subperiosteal tunneling access (VISTA) with platelet-rich fibrin will be used to achieve complete root coverage.

NCT ID: NCT03588494 Not yet recruiting - Quality of Life Clinical Trials

Endostar in Combination With Chemoradiotherapy in Patient With Advanced Non-small Cell Lung Cancer

Start date: August 1, 2018
Phase: Phase 2/Phase 3
Study type: Interventional

To investigate the safety and efficacy recombinant human endostatin(endostar) durative transfusion combined with cocurrent chemoradiotherapy in advanced non-small cell lung cancer(NSCLC).

NCT ID: NCT03588858 Not yet recruiting - Clinical trials for Work-Related Condition

Child Labour at Al-Sadat Neighborhood, Assiut City

Start date: August 1, 2018
Phase:
Study type: Observational

General objective: To promote proper health status of working children in Assiut city. Specific objectives: 1. To describe the socio-demographic characteristics of children working in car repair workshops in Al-Sadat area of Assiut city. 2. To describe the work environment. 3. To identify work related injuries and diseases among those working children.

NCT ID: NCT03589950 Not yet recruiting - Lung Neoplasms Clinical Trials

Anlotinib Plus Chemotherapy for Patients With Advanced Non-small Cell Lung Cancer

Start date: August 1, 2018
Phase: Phase 2
Study type: Interventional

Anlotibib (AL3818) is a kind of innovative medicines approved by State Food and Drug Administration(SFDA:2011L00661) which was researched by Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd. Anlotinib is a kinase inhibitor of receptor tyrosine with multi-targets, especially for VEGFR2、VEGFR3、PDGFRβ and c-Kit. It has the obvious resistance to new angiogenesis. The trial is to explore Anlotinib for the effectiveness and safety of advanced non-small cell lung cancer who failed first lines of chemotherapy

NCT ID: NCT03591549 Not yet recruiting - Clinical trials for Metastatic Breast Cancer

Fulvestrant in Metastatic Breast Cancer

Start date: August 1, 2018
Phase: Phase 4
Study type: Interventional

This is a prospective study of the role of fulvestrant in combination with ovarian function suppression as first-line therapy in premenopausal patients with metastatic hormone receptor-positive breast cancer.

NCT ID: NCT03591939 Not yet recruiting - Clinical trials for Diabetic Nephropathy Type 2

T-regulatory Cells in Diabetic Type Two Nephropathy

Start date: August 1, 2018
Phase:
Study type: Observational

Diabetes mellitus is one of the most prevalent health problems worldwide. Diabetic nephropathy has become the leading cause of end-stage kidney disease worldwide and is associated with an increased cardiovascular risk. Traditionally, metabolic and hemodynamic factors are the main causes of renal lesions in patients with type two diabetes mellitus and diabetic nephropathy , both considered non-immune diseases. Serial researches has demonstrated that diabetic nephropathy is a metabolic and hemodynamic disorder, with inflammation playing a vital role in the process.

NCT ID: NCT03595865 Not yet recruiting - Glaucoma; Drugs Clinical Trials

Efficacy of Tafluprost as an Adjunct to Medical Therapy for Residual Glaucoma After Trabeculectomy

Start date: August 1, 2018
Phase: N/A
Study type: Interventional

A 6-month, parallel-group study of the safety and efficacy of tafluprostin for Chinese patients with posttrabeculectomy residual primary angle-closure glaucoma or posttrabeculectomy residual primary open angle glaucoma.

NCT ID: NCT03596840 Not yet recruiting - Hypertension Clinical Trials

Community-based Microalbuminuria Screening in Patients With Hypertension

CMSIH
Start date: August 1, 2018
Phase:
Study type: Observational

This study evaluates the effectiveness of different anti-hypertensive drugs on patients with hypertension and microalbuminuria.

NCT ID: NCT03597932 Not yet recruiting - Anesthesia Clinical Trials

Intraoperative Handover Checklist of Anesthesia Care Improves Outcomes Among Patients Undergoing Major Surgery

Start date: August 1, 2018
Phase:
Study type: Observational [Patient Registry]

Implementation of a standardized handover checklist for intraoperative anesthesia care transition attenuates burnout among anesthesiologists and improves postoperative outcomes of patients undergoing major surgery , both of which benefit the quality of patient care and the development of anesthesiology.